×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. I consent to receive medical updates and communications from eMediNexus, it's parent company IJCP and its industry partners.

LAICON 2022 International: Lipid and Lab Reporting

  494 Views

Dr Nimmi Kansal, New Delhi    01 October 2022

  • Nonfasting samples can be used to measure total cholesterol (TC), HDL-C and HDL-C.
  • TG can be measured in a nonfasting state, but reference intervals in a nonfasting form must be established for the same in larger populations.
  • For patients, laboratories and clinicians, nonfasting lipid profiles represent a simplification without negative implications for CVD prevention for prognostic, diagnostic and therapeutic options.
  • The burden of ASCVD in India is alarmingly high and is a cause of concern.
  • In patients with established ASCVD, treatment decisions pertaining to the use of preventive CV therapies are relatively straightforward as all patients require aggressive risk reduction.
  • However, in patients who do not have pre-existing ASCVD, i.e., those requiring primary prevention of ASCVD, wide heterogeneity in the likelihood of developing ASCVD necessitates some form of risk stratification.
  • Now is the time to formulate a lipid profile report that gives personalized risk stratification to the patients, as the knowledge of the anticipated ASCVD risk may help improve patients’ health-related behaviors and compliance with the interventions.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.